RAD51C and breast cancer: The population‐based approach used in this study to investigate the recurrent RAD51C c.571 + 4A > G VUS confirm that: (a) RAD51C c.571 + 4A > G is pathogenic; (b) RAD51C c.571 + 4A > G is over represented in NL HBOC patients; (c) RAD51C is associated with BC in addition to OC in these families; and (d) RAD51C should be considered for inclusion on multigene panels for incident BC and OC cases in NL.